BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sidhu SS, Goyal O, Mishra BP, Sood A, Chhina RS, Soni RK. Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial). Am J Gastroenterol. 2011;106:307-316. [PMID: 21157444 DOI: 10.1038/ajg.2010.455] [Cited by in Crossref: 155] [Cited by in F6Publishing: 138] [Article Influence: 14.1] [Reference Citation Analysis]
Number Citing Articles
1 Rathi S, Chopra M, Chouduri G, Sharma P, Madan K, Chhabra M, Rai RR, Govil A, Konar A, Goenka M, Agarwal M, Mukherjee J, Thorat V, Salunkhe S, Abraham P, Nagral A, Jhaveri A, Bhat N, Varghese J, R S A, Ravishankar, Reddy DC, Dhiman RK. Prevalence of Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis: A Cross-Sectional, Clinicoepidemiological, Multicenter, Nationwide Study in India: The PREDICT Study. J Clin Exp Hepatol 2019;9:476-83. [PMID: 31516264 DOI: 10.1016/j.jceh.2018.09.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
2 Hanai T, Shiraki M, Watanabe S, Imai K, Suetsugu A, Takai K, Moriwaki H, Shimizu M. Prognostic significance of minimal hepatic encephalopathy in patients with liver cirrhosis in Japan: A propensity score-matching analysis. J Gastroenterol Hepatol 2019;34:1809-16. [PMID: 30779213 DOI: 10.1111/jgh.14635] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
3 叶江锋, 琚坚. 利福昔明预防和治疗肝性脑病的研究进展. 世界华人消化杂志 2015; 23(7): 1090-1096 [DOI: 10.11569/wcjd.v23.i7.1090] [Reference Citation Analysis]
4 White H. Neurologic manifestations of acute and chronic liver disease. Continuum (Minneap Minn). 2014;20:670-680. [PMID: 24893241 DOI: 10.1212/01.con.0000450973.84075.a7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Quigley EM, Monsour HP. The gut microbiota and the liver: implications for clinical practice. Expert Rev Gastroenterol Hepatol 2013;7:723-32. [PMID: 24134195 DOI: 10.1586/17474124.2013.848167] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
6 Han X, Luo Z, Wang W, Zheng P, Li T, Mei Z, Wang J. Efficacy and Safety of Rifaximin Versus Placebo or Other Active Drugs in Critical ill Patients With Hepatic Encephalopathy. Front Pharmacol 2021;12:696065. [PMID: 34690751 DOI: 10.3389/fphar.2021.696065] [Reference Citation Analysis]
7 Taneja S, Dhiman RK, Khatri A, Goyal S, Thumbru KK, Agarwal R, Duseja A, Chawla Y. Inhibitory control test for the detection of minimal hepatic encephalopathy in patients with cirrhosis of liver. J Clin Exp Hepatol. 2012;2:306-314. [PMID: 25755452 DOI: 10.1016/j.jceh.2012.07.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
8 Arasaradnam RP, McFarlane M, Ling K, Wurie S, O'Connell N, Nwokolo CU, Bardhan KD, Skinner J, Savage RS, Covington JA. Breathomics--exhaled volatile organic compound analysis to detect hepatic encephalopathy: A pilot study. J Breath Res. 2016;10:016012. [PMID: 26866470 DOI: 10.1088/1752-7155/10/1/016012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
9 Torlot FJ, McPhail MJ, Taylor-Robinson SD. Meta-analysis: The diagnostic accuracy of critical flicker frequency in minimal hepatic encephalopathy. Aliment Pharmacol Ther. 2013;37:527-536. [PMID: 23293917 DOI: 10.1111/apt.12199] [Cited by in Crossref: 55] [Cited by in F6Publishing: 40] [Article Influence: 6.9] [Reference Citation Analysis]
10 Tartaglione EV, Derleth M, Yu L, Ioannou GN. Can computerized brain training games be used to identify early cognitive impairment in cirrhosis? Am J Gastroenterol 2014;109:316-23. [PMID: 24594947 DOI: 10.1038/ajg.2013.306] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
11 Stawicka A, Jaroszewicz J, Zbrzeźniak J, Sołowianowicz N, Woszczenko A, Świderska M, Flisiak R. Clinical Usefulness of the Inhibitory Control Test (ICT) in the Diagnosis of Minimal Hepatic Encephalopathy. Int J Environ Res Public Health 2020;17:E3645. [PMID: 32455895 DOI: 10.3390/ijerph17103645] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Kimer N, Krag A, Møller S, Bendtsen F, Gluud LL. Systematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathy. Aliment Pharmacol Ther 2014;40:123-32. [DOI: 10.1111/apt.12803] [Cited by in Crossref: 109] [Cited by in F6Publishing: 77] [Article Influence: 15.6] [Reference Citation Analysis]
13 Garcovich M, Zocco MA, Roccarina D, Ponziani FR, Gasbarrini A. Prevention and treatment of hepatic encephalopathy: Focusing on gut microbiota. World J Gastroenterol 2012; 18(46): 6693-6700 [PMID: 23239905 DOI: 10.3748/wjg.v18.i46.6693] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 37] [Article Influence: 4.2] [Reference Citation Analysis]
14 Schulz C, Schütte K, Kropf S, Schmitt FC, Vasapolli R, Kliegis LM, Riegger A, Malfertheiner P. RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial. Trials. 2016;17:111. [PMID: 26926775 DOI: 10.1186/s13063-016-1205-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
15 Ridola L, Cardinale V, Riggio O. The burden of minimal hepatic encephalopathy: From diagnosis to therapeutic strategies. Ann Gastroenterol. 2018;31:151-164. [PMID: 29507462 DOI: 10.20524/aog.2018.0232] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
16 Zullo A, Hassan C, Lorenzetti R. Rifaximin therapy in minimal hepatic encephalopathy cirrhotics. Am J Gastroenterol. 2011;106:2041; author reply 2041-2042. [PMID: 22056578 DOI: 10.1038/ajg.2011.216] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
17 Sharma P, Sharma BC. A survey of patterns of practice and perception of minimal hepatic encephalopathy: a nationwide survey in India. Saudi J Gastroenterol 2014;20:304-8. [PMID: 25253366 DOI: 10.4103/1319-3767.141692] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
18 Sanyal A, Younossi ZM, Bass NM, Mullen KD, Poordad F, Brown RS, Vemuru RP, Mazen Jamal M, Huang S, Merchant K, Bortey E, Forbes WP. Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2011;34:853-861. [PMID: 21848797 DOI: 10.1111/j.1365-2036.2011.04808.x] [Cited by in Crossref: 91] [Cited by in F6Publishing: 78] [Article Influence: 9.1] [Reference Citation Analysis]
19 Bajaj JS, Thacker LR, Wade JB, Sanyal AJ, Heuman DM, Sterling RK, Gibson DP, Stravitz RT, Puri P, Fuchs M. PROMIS computerised adaptive tests are dynamic instruments to measure health-related quality of life in patients with cirrhosis. Aliment Pharmacol Ther. 2011;34:1123-1132. [PMID: 21929591 DOI: 10.1111/j.1365-2036.2011.04842.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 5.3] [Reference Citation Analysis]
20 Ando Y, Ishigami M, Ito T, Ishizu Y, Kuzuya T, Honda T, Ishikawa T, Fujishiro M. Sarcopenia impairs health-related quality of life in cirrhotic patients. Eur J Gastroenterol Hepatol 2019;31:1550-6. [PMID: 31206408 DOI: 10.1097/MEG.0000000000001472] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
21 Moran S, López-Sánchez M, Milke-García MDP, Rodríguez-Leal G. Current approach to treatment of minimal hepatic encephalopathy in patients with liver cirrhosis. World J Gastroenterol 2021; 27(22): 3050-3063 [PMID: 34168407 DOI: 10.3748/wjg.v27.i22.3050] [Reference Citation Analysis]
22 Lauridsen MM, Mikkelsen S, Svensson T, Holm J, Klüver C, Gram J, Vilstrup H, Schaffalitzky de Muckadell OB. The continuous reaction time test for minimal hepatic encephalopathy validated by a randomized controlled multi-modal intervention-A pilot study. PLoS One 2017;12:e0185412. [PMID: 29020023 DOI: 10.1371/journal.pone.0185412] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
23 Sheasgreen C, Lu L, Patel A. Pathophysiology, diagnosis, and management of hepatic encephalopathy. Inflammopharmacol 2014;22:319-26. [DOI: 10.1007/s10787-014-0217-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
24 Henao-Mejia J, Elinav E, Thaiss CA, Licona-Limon P, Flavell RA. Role of the intestinal microbiome in liver disease. J Autoimmun. 2013;46:66-73. [PMID: 24075647 DOI: 10.1016/j.jaut.2013.07.001] [Cited by in Crossref: 106] [Cited by in F6Publishing: 95] [Article Influence: 13.3] [Reference Citation Analysis]
25 Hu X, Wang T, Jin F. Alzheimer’s disease and gut microbiota. Sci China Life Sci 2016;59:1006-23. [DOI: 10.1007/s11427-016-5083-9] [Cited by in Crossref: 143] [Cited by in F6Publishing: 121] [Article Influence: 28.6] [Reference Citation Analysis]
26 Burkard T, Biedermann A, Herold C, Dietlein M, Rauch M, Diefenbach M. Treatment with a potassium-iron-phosphate-citrate complex improves PSE scores and quality of life in patients with minimal hepatic encephalopathy: a multicenter, randomized, placebo-controlled, double-blind clinical trial. Eur J Gastroenterol Hepatol. 2013;25:352-358. [PMID: 23117470 DOI: 10.1097/MEG.0b013e32835afaa5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
27 Qi R, Zhang LJ, Zhong J, Zhang Z, Ni L, Jiao Q, Liao W, Zheng G, Lu G. Altered effective connectivity network of the basal ganglia in low-grade hepatic encephalopathy: a resting-state fMRI study with Granger causality analysis. PLoS One. 2013;8:e53677. [PMID: 23326484 DOI: 10.1371/journal.pone.0053677] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
28 Lauridsen MM, Grønbæk H, Næser EB, Leth ST, Vilstrup H. Gender and age effects on the continuous reaction times method in volunteers and patients with cirrhosis. Metab Brain Dis 2012;27:559-65. [DOI: 10.1007/s11011-012-9318-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
29 Waghray A, Waghray N, Mullen K. Management of covert hepatic encephalopathy. J Clin Exp Hepatol 2015;5:S75-81. [PMID: 26041963 DOI: 10.1016/j.jceh.2014.02.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
30 Moratalla A, Ampuero J, Bellot P, Gallego-Durán R, Zapater P, Roger M, Figueruela B, Martínez-Moreno B, González-Navajas JM, Such J, Romero-Gómez M, Francés R. Lactulose reduces bacterial DNA translocation, which worsens neurocognitive shape in cirrhotic patients with minimal hepatic encephalopathy. Liver Int 2017;37:212-23. [PMID: 27388776 DOI: 10.1111/liv.13200] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
31 Acharya C, Bajaj JS. Current Management of Hepatic Encephalopathy. Am J Gastroenterol. 2018;113:1600-1612. [PMID: 30002466 DOI: 10.1038/s41395-018-0179-4] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 14.0] [Reference Citation Analysis]
32 Sharma P, Sharma BC. Disaccharides in the treatment of hepatic encephalopathy. Metab Brain Dis 2013;28:313-20. [PMID: 23456517 DOI: 10.1007/s11011-013-9392-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
33 Pawar VB, Surude RG, Sonthalia N, Zanwar V, Jain S, Contractor Q, Rathi PM. Minimal Hepatic Encephalopathy in Indians: Psychometric Hepatic Encephalopathy Score and Inhibitory Control Test for Diagnosis and Rifaximin or Lactulose for Its Reversal. J Clin Transl Hepatol. 2019;7:304-312. [PMID: 31915599 DOI: 10.14218/jcth.2017.00037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 De Rui M, Montagnese S, Amodio P. Recent developments in the diagnosis and treatment of covert/minimal hepatic encephalopathy. Expert Rev Gastroenterol Hepatol 2016;10:443-50. [PMID: 26758861 DOI: 10.1586/17474124.2016.1141675] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
35 Moscucci F, Nardelli S, Pentassuglio I, Pasquale C, Ridola L, Merli M, Riggio O. Previous overt hepatic encephalopathy rather than minimal hepatic encephalopathy impairs health-related quality of life in cirrhotic patients. Liver Int 2011;31:1505-10. [PMID: 22093325 DOI: 10.1111/j.1478-3231.2011.02598.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 3.2] [Reference Citation Analysis]
36 Greinert R, Ripoll C, Hollenbach M, Zipprich A. Stepwise diagnosis in covert hepatic encephalopathy: critical flicker frequency and MELD-score as a first-step approach. Aliment Pharmacol Ther 2016;44:514-21. [PMID: 27385440 DOI: 10.1111/apt.13721] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
37 Mangas-Losada A, García-García R, Leone P, Ballester MP, Cabrera-Pastor A, Urios A, Gallego JJ, Martínez-Pretel JJ, Giménez-Garzó C, Revert F, Escudero-García D, Tosca J, Ríos MP, Montón C, Durbán L, Aparicio L, Montoliu C, Felipo V. Selective improvement by rifaximin of changes in the immunophenotype in patients who improve minimal hepatic encephalopathy. J Transl Med 2019;17:293. [PMID: 31462286 DOI: 10.1186/s12967-019-2046-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
38 Spengler U. Management of end-stage liver disease in HIV/hepatitis C virus co-infection: . Current Opinion in HIV and AIDS 2011;6:527-33. [DOI: 10.1097/coh.0b013e32834bc691] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
39 Bhanji RA, Carey EJ, Watt KD. Review article: maximising quality of life while aspiring for quantity of life in end-stage liver disease. Aliment Pharmacol Ther. 2017;46:16-25. [PMID: 28464346 DOI: 10.1111/apt.14078] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
40 Lee Y, Kim C, Suk KT, Choi HC, Bang CS, Yoon JH, Baik GH, Kim DJ, Jang MU, Sohn JH. Differences in cognitive function between patients with viral and alcoholic compensated liver cirrhosis. Metab Brain Dis 2016;31:369-76. [DOI: 10.1007/s11011-015-9761-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
41 de Wit K, Schaapman JJ, Nevens F, Verbeek J, Coenen S, Cuperus FJC, Kramer M, Tjwa ETTL, Mostafavi N, Dijkgraaf MGW, van Delden OM, Beuers UHW, Coenraad MJ, Takkenberg RB. Prevention of hepatic encephalopathy by administration of rifaximin and lactulose in patients with liver cirrhosis undergoing placement of a transjugular intrahepatic portosystemic shunt (TIPS): a multicentre randomised, double blind, placebo controlled trial (PEARL trial). BMJ Open Gastroenterol 2020;7:e000531. [PMID: 33372103 DOI: 10.1136/bmjgast-2020-000531] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Sauerbruch T, Appenrodt B, Schmitz V, Spengler U. The conservative and interventional treatment of the complications of liver cirrhosis: Part 2 of a series on liver cirrhosis. Dtsch Arztebl Int 2013;110:126-32, I. [PMID: 23505400 DOI: 10.3238/arztebl.2013.0126] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
43 Stinton LM, Jayakumar S. Minimal hepatic encephalopathy. Can J Gastroenterol 2013;27:572-4. [PMID: 24106728 DOI: 10.1155/2013/547670] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
44 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications. Clin Mol Hepatol 2020;26:83-127. [PMID: 31918536 DOI: 10.3350/cmh.2019.0010n] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 14.0] [Reference Citation Analysis]
45 Cai X, Wang L, Hu C. Retracted : Efficacy of different drugs in the treatment of minimal hepatic encephalopathy: A network meta‐analysis involving 826 patients based on 10 randomized controlled trials. J Cell Biochem 2018;119:8336-45. [DOI: 10.1002/jcb.26886] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
46 Bajaj JS, Hylemon PB, Younossi Z. The Intestinal Microbiota and Liver Disease. Am J Gastroenterol Suppl 2012;1:9-14. [DOI: 10.1038/ajgsup.2012.3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 11] [Article Influence: 3.4] [Reference Citation Analysis]
47 李莹, 韩涛. 肝硬化合并细菌感染易感性机制的研究进展. 世界华人消化杂志 2015; 23(22): 3560-3566 [DOI: 10.11569/wcjd.v23.i22.3560] [Reference Citation Analysis]
48 Solà E, Watson H, Graupera I, Turón F, Barreto R, Rodríguez E, Pavesi M, Arroyo V, Guevara M, Ginès P. Factors related to quality of life in patients with cirrhosis and ascites: relevance of serum sodium concentration and leg edema. J Hepatol. 2012;57:1199-1206. [PMID: 22824819 DOI: 10.1016/j.jhep.2012.07.020] [Cited by in Crossref: 78] [Cited by in F6Publishing: 67] [Article Influence: 8.7] [Reference Citation Analysis]
49 Mullen KD, Prakash RK. Management of covert hepatic encephalopathy. Clin Liver Dis. 2012;16:91-93. [PMID: 22321467 DOI: 10.1016/j.cld.2011.12.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
50 Kc M, Olson APJ, Wang Q, Lim N. Unexpected clinical outcomes following the implementation of a standardised order set for hepatic encephalopathy. BMJ Open Gastroenterol 2021;8:e000621. [PMID: 33866310 DOI: 10.1136/bmjgast-2021-000621] [Reference Citation Analysis]
51 Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, Kawaguchi T, Kurosaki M, Sakaida I, Shimizu M, Taniai M, Terai S, Nishikawa H, Hiasa Y, Hidaka H, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K. Evidence-based clinical practice guidelines for liver cirrhosis 2020. Hepatol Res 2021;51:725-49. [PMID: 34228859 DOI: 10.1111/hepr.13678] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
52 Teperman LW. Impact of pretransplant hepatic encephalopathy on liver posttransplantation outcomes. Int J Hepatol 2013;2013:952828. [PMID: 24324895 DOI: 10.1155/2013/952828] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
53 Agrawal S, Umapathy S, Dhiman RK. Minimal hepatic encephalopathy impairs quality of life. J Clin Exp Hepatol. 2015;5:S42-S48. [PMID: 26041957 DOI: 10.1016/j.jceh.2014.11.006] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 5.4] [Reference Citation Analysis]
54 Li X, Gan D, Li Y, Zhang P, Li Z, Du H, Zhang L, Cheng Y, Zhang Y, Liang Y, Ye Y. JianPi HuaZhuo XingNao formula (Chinese herbal medicine) for the treatment of minimal hepatic encephalopathy: a protocol for a randomized, placebo-controlled pilot trial. Medicine (Baltimore) 2018;97:e0526. [PMID: 29703024 DOI: 10.1097/MD.0000000000010526] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
55 Bajaj JS, Thacker LR, Heuman DM, Fuchs M, Sterling RK, Sanyal AJ, Puri P, Siddiqui MS, Stravitz RT, Bouneva I, Luketic V, Noble N, White MB, Monteith P, Unser A, Wade JB. The Stroop smartphone application is a short and valid method to screen for minimal hepatic encephalopathy. Hepatology. 2013;58:1122-1132. [PMID: 23389962 DOI: 10.1002/hep.26309] [Cited by in Crossref: 111] [Cited by in F6Publishing: 95] [Article Influence: 13.9] [Reference Citation Analysis]
56 Suzuki K, Endo R, Takikawa Y, Moriyasu F, Aoyagi Y, Moriwaki H, Terai S, Sakaida I, Sakai Y, Nishiguchi S, Ishikawa T, Takagi H, Naganuma A, Genda T, Ichida T, Takaguchi K, Miyazawa K, Okita K. Efficacy and safety of rifaximin in Japanese patients with hepatic encephalopathy: A phase II/III, multicenter, randomized, evaluator-blinded, active-controlled trial and a phase III, multicenter, open trial. Hepatol Res. 2018;48:411-423. [PMID: 29235218 DOI: 10.1111/hepr.13045] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
57 Bajaj JS, Pinkerton SD, Sanyal AJ, Heuman DM. Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis. Hepatology 2012;55:1164-71. [PMID: 22135042 DOI: 10.1002/hep.25507] [Cited by in Crossref: 85] [Cited by in F6Publishing: 73] [Article Influence: 9.4] [Reference Citation Analysis]
58 Qi R, Xu Q, Zhang LJ, Zhong J, Zheng G, Wu S, Zhang Z, Liao W, Zhong Y, Ni L. Structural and functional abnormalities of default mode network in minimal hepatic encephalopathy: a study combining DTI and fMRI. PLoS One. 2012;7:e41376. [PMID: 22911787 DOI: 10.1371/journal.pone.0041376] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 4.6] [Reference Citation Analysis]
59 Sunil HV, Mittal BR, Kurmi R, Chawla YK, Dhiman RK. Brain perfusion single photon emission computed tomography abnormalities in patients with minimal hepatic encephalopathy. J Clin Exp Hepatol 2012;2:116-21. [PMID: 25755420 DOI: 10.1016/S0973-6883(12)60099-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
60 Toapanta-yanchapaxi L, López-velázquez JA, Uribe M, Méndez-sánchez N. Minimal hepatic encephalopathy. Should we treat it? Annals of Hepatology 2013;12:487-92. [DOI: 10.1016/s1665-2681(19)31013-0] [Cited by in Crossref: 4] [Article Influence: 0.5] [Reference Citation Analysis]
61 Henao-Mejia J, Elinav E, Thaiss CA, Flavell RA. The intestinal microbiota in chronic liver disease. Adv Immunol. 2013;117:73-97. [PMID: 23611286 DOI: 10.1016/b978-0-12-410524-9.00003-7] [Cited by in Crossref: 36] [Cited by in F6Publishing: 24] [Article Influence: 4.5] [Reference Citation Analysis]
62 American Association for the Study of Liver Diseases. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. J Hepatol. 2014;61:642-659. [PMID: 25015420 DOI: 10.1016/j.jhep.2014.05.042] [Cited by in Crossref: 212] [Cited by in F6Publishing: 164] [Article Influence: 30.3] [Reference Citation Analysis]
63 Kappus MR, Bajaj JS. Covert hepatic encephalopathy: Not as minimal as you might think. Clin Gastroenterol Hepatol. 2012;10:1208-1219. [PMID: 22728384 DOI: 10.1016/j.cgh.2012.05.026] [Cited by in Crossref: 55] [Cited by in F6Publishing: 41] [Article Influence: 6.1] [Reference Citation Analysis]
64 Victor DW 3rd, Quigley EM. Hepatic encephalopathy involves interactions among the microbiota, gut, brain. Clin Gastroenterol Hepatol. 2014;12:1009-1011. [PMID: 24462627 DOI: 10.1016/j.cgh.2014.01.022] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
65 Prakash RK, Kanna S, Mullen KD. Evolving Concepts: The Negative Effect of Minimal Hepatic Encephalopathy and Role for Prophylaxis in Patients With Cirrhosis. Clinical Therapeutics 2013;35:1458-73. [DOI: 10.1016/j.clinthera.2013.07.421] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
66 Sidhu SS, Goyal O, Parker RA, Kishore H, Sood A. Rifaximin vs. lactulose in treatment of minimal hepatic encephalopathy. Liver Int. 2016;36:378-385. [PMID: 26201713 DOI: 10.1111/liv.12921] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
67 Ferenci P. Hepatic encephalopathy. Gastroenterol Rep (Oxf). 2017;5:138-147. [PMID: 28533911 DOI: 10.1093/gastro/gox013] [Cited by in Crossref: 44] [Cited by in F6Publishing: 32] [Article Influence: 11.0] [Reference Citation Analysis]
68 Taniguchi E, Kawaguchi T, Sakata M, Itou M, Oriishi T, Sata M. Lipid profile is associated with the incidence of cognitive dysfunction in viral cirrhotic patients: A data-mining analysis: Cognition-related lipid profile in liver cirrhosis. Hepatology Research 2013;43:418-24. [DOI: 10.1111/j.1872-034x.2012.01076.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
69 Ahluwalia V, Wade JB, Heuman DM, Hammeke TA, Sanyal AJ, Sterling RK, Stravitz RT, Luketic V, Siddiqui MS, Puri P, Fuchs M, Lennon MJ, Kraft KA, Gilles H, White MB, Noble NA, Bajaj JS. Enhancement of functional connectivity, working memory and inhibitory control on multi-modal brain MR imaging with Rifaximin in Cirrhosis: implications for the gut-liver-brain axis. Metab Brain Dis. 2014;29:1017-1025. [PMID: 24590688 DOI: 10.1007/s11011-014-9507-6] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 6.9] [Reference Citation Analysis]
70 Patel VC, White H, Støy S, Bajaj JS, Shawcross DL. Clinical science workshop: targeting the gut-liver-brain axis. Metab Brain Dis 2016;31:1327-37. [PMID: 26446022 DOI: 10.1007/s11011-015-9743-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
71 Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, Kawaguchi T, Kurosaki M, Sakaida I, Shimizu M, Taniai M, Terai S, Nishikawa H, Hiasa Y, Hidaka H, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K. Evidence-based clinical practice guidelines for Liver Cirrhosis 2020. J Gastroenterol 2021;56:593-619. [PMID: 34231046 DOI: 10.1007/s00535-021-01788-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
72 Romero-gómez M, Ampuero J. Deciphering the Spectrum of Low-Grade Hepatic Encephalopathy in Clinical Practice. Gastroenterology 2014;146:887-90. [DOI: 10.1053/j.gastro.2014.02.019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
73 Ponziani FR, Gerardi V, Pecere S, D’Aversa F, Lopetuso L, Zocco MA, Pompili M, Gasbarrini A. Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications. World J Gastroenterol 2015; 21(43): 12322-12333 [PMID: 26604640 DOI: 10.3748/wjg.v21.i43.12322] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 33] [Article Influence: 6.2] [Reference Citation Analysis]
74 Patel D, Mcphail M, Cobbold J, Taylor-robinson S. Hepatic encephalopathy. British Journal of Hospital Medicine 2012;73:79-85. [DOI: 10.12968/hmed.2012.73.2.79] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
75 Rudler M, Weiss N, Bouzbib C, Thabut D. Diagnosis and Management of Hepatic Encephalopathy. Clin Liver Dis 2021;25:393-417. [PMID: 33838857 DOI: 10.1016/j.cld.2021.01.008] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
76 Bianchi G, Giovagnoli M, Sasdelli AS, Marchesini G. Hepatic encephalopathy and health-related quality of life. Clin Liver Dis 2012;16:159-70. [PMID: 22321471 DOI: 10.1016/j.cld.2011.12.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
77 Ridola L, Nardelli S, Gioia S, Riggio O. Quality of life in patients with minimal hepatic encephalopathy. World J Gastroenterol 2018; 24(48): 5446-5453 [PMID: 30622374 DOI: 10.3748/wjg.v24.i48.5446] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]
78 Bellot P, Francés R, Such J. Pathological bacterial translocation in cirrhosis: pathophysiology, diagnosis and clinical implications. Liver Int 2013;33:31-9. [DOI: 10.1111/liv.12021] [Cited by in Crossref: 133] [Cited by in F6Publishing: 138] [Article Influence: 14.8] [Reference Citation Analysis]
79 Prakash RK, Mullen KD. Is poor quality of life always present with minimal hepatic encephalopathy? Liver Int 2011;31:908-10. [PMID: 21733080 DOI: 10.1111/j.1478-3231.2011.02532.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
80 Iadevaia MD, Prete AD, Cesaro C, Gaeta L, Zulli C, Loguercio C. Rifaximin in the treatment of hepatic encephalopathy. Hepat Med. 2011;3:109-117. [PMID: 24367227 DOI: 10.2147/hmer.s11988] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
81 Patidar KR, Bajaj JS. Antibiotics for the treatment of hepatic encephalopathy. Metab Brain Dis 2013;28:307-12. [PMID: 23389621 DOI: 10.1007/s11011-013-9383-5] [Cited by in Crossref: 58] [Cited by in F6Publishing: 35] [Article Influence: 7.3] [Reference Citation Analysis]
82 Åberg F. From prolonging life to prolonging working life: Tackling unemployment among liver-transplant recipients. World J Gastroenterol 2016; 22(14): 3701-3711 [PMID: 27076755 DOI: 10.3748/wjg.v22.i14.3701] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
83 Miwa T, Hanai T, Toshihide M, Ogiso Y, Imai K, Suetsugu A, Takai K, Shiraki M, Katsumura N, Shimizu M. Zinc deficiency predicts overt hepatic encephalopathy and mortality in liver cirrhosis patients with minimal hepatic encephalopathy. Hepatol Res 2021;51:662-73. [PMID: 33242359 DOI: 10.1111/hepr.13601] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
84 Montagnese S, Russo FP, Amodio P, Burra P, Gasbarrini A, Loguercio C, Marchesini G, Merli M, Ponziani FR, Riggio O, Scarpignato C. Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). Dig Liver Dis. 2019;51:190-205. [PMID: 30606696 DOI: 10.1016/j.dld.2018.11.035] [Cited by in Crossref: 30] [Cited by in F6Publishing: 18] [Article Influence: 10.0] [Reference Citation Analysis]
85 Quigley EM, Stanton C, Murphy EF. The gut microbiota and the liver. Pathophysiological and clinical implications. J Hepatol. 2013;58:1020-1027. [PMID: 23183530 DOI: 10.1016/j.jhep.2012.11.023] [Cited by in Crossref: 75] [Cited by in F6Publishing: 68] [Article Influence: 8.3] [Reference Citation Analysis]
86 Woodhouse CA, Patel VC, Singanayagam A, Shawcross DL. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease. Aliment Pharmacol Ther. 2018;47:192-202. [PMID: 29083037 DOI: 10.1111/apt.14397] [Cited by in Crossref: 78] [Cited by in F6Publishing: 70] [Article Influence: 19.5] [Reference Citation Analysis]
87 Bruyneel M, Sersté T. Sleep disturbances in patients with liver cirrhosis: prevalence, impact, and management challenges. Nat Sci Sleep 2018;10:369-75. [PMID: 30464664 DOI: 10.2147/NSS.S186665] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
88 Nishikawa H, Enomoto H, Nishiguchi S, Iijima H. Liver Cirrhosis and Sarcopenia from the Viewpoint of Dysbiosis. Int J Mol Sci. 2020;21:5254. [PMID: 32722100 DOI: 10.3390/ijms21155254] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
89 Neff GW, Kemmer N, Duncan C, Alsina A. Update on the management of cirrhosis - focus on cost-effective preventative strategies. Clinicoecon Outcomes Res 2013;5:143-52. [PMID: 23626470 DOI: 10.2147/CEOR.S30675] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
90 Patidar KR, Bajaj JS. Covert and Overt Hepatic Encephalopathy: Diagnosis and Management. Clin Gastroenterol Hepatol 2015;13:2048-61. [PMID: 26164219 DOI: 10.1016/j.cgh.2015.06.039] [Cited by in Crossref: 87] [Cited by in F6Publishing: 65] [Article Influence: 14.5] [Reference Citation Analysis]
91 Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology. 2014;146:1513-1524. [PMID: 24440671 DOI: 10.1053/j.gastro.2014.01.020] [Cited by in Crossref: 487] [Cited by in F6Publishing: 467] [Article Influence: 69.6] [Reference Citation Analysis]
92 Dhiman RK, Thumburu KK, Verma N, Chopra M, Rathi S, Dutta U, Singal AK, Taneja S, Duseja A, Singh M. Comparative Efficacy of Treatment Options for Minimal Hepatic Encephalopathy: A Systematic Review and Network Meta-Analysis.Clin Gastroenterol Hepatol. 2020;18:800-812.e25. [PMID: 31476436 DOI: 10.1016/j.cgh.2019.08.047] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
93 Allampati S, Mullen KD. Nomenclature and definition of hepatic encephalopathy - An update. Clin Liver Dis (Hoboken) 2015;5:68-70. [PMID: 31040953 DOI: 10.1002/cld.449] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
94 Flamm SL. Covert Hepatic Encephalopathy: Who Should Be Tested and Treated? Clin Liver Dis 2015;19:473-85. [PMID: 26195202 DOI: 10.1016/j.cld.2015.04.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
95 Koutsounas I, Kaltsa G, Siakavellas SI, Bamias G. Markers of bacterial translocation in end-stage liver disease. World J Hepatol 2015; 7(20): 2264-2273 [PMID: 26380651 DOI: 10.4254/wjh.v7.i20.2264] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
96 Bajaj JS, Thacker LR, Heuman DM, Gibson DP, Sterling RK, Stravitz RT, Fuchs M, Sanyal AJ, Wade JB. Driving simulation can improve insight into impaired driving skills in cirrhosis. Dig Dis Sci 2012;57:554-60. [PMID: 21901255 DOI: 10.1007/s10620-011-1888-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
97 Bruetto RG, Rodrigues FB, Torres US, Otaviano AP, Zanetta DM, Burdmann EA. Renal function at hospital admission and mortality due to acute kidney injury after myocardial infarction. PLoS One. 2012;7:e35496. [PMID: 22539974 DOI: 10.1371/journal.pone] [Cited by in F6Publishing: 89] [Reference Citation Analysis]
98 Mangas-Losada A, García-García R, Urios A, Escudero-García D, Tosca J, Giner-Durán R, Serra MA, Montoliu C, Felipo V. Minimal hepatic encephalopathy is associated with expansion and activation of CD4+CD28-, Th22 and Tfh and B lymphocytes. Sci Rep 2017;7:6683. [PMID: 28751644 DOI: 10.1038/s41598-017-05938-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
99 Mina A, Moran S, Ortiz-Olvera N, Mera R, Uribe M. Prevalence of minimal hepatic encephalopathy and quality of life in patients with decompensated cirrhosis. Hepatol Res. 2014;44:E92-E99. [PMID: 24033755 DOI: 10.1111/hepr.12227] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
100 Kimer N, Krag A, Gluud LL. Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy. Patient Prefer Adherence. 2014;8:331-338. [PMID: 24672227 DOI: 10.2147/PPA.S41565] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
101 Tsochatzis EA, Bosch J, Burroughs AK. New therapeutic paradigm for patients with cirrhosis. Hepatology. 2012;56:1983-1992. [PMID: 22729954 DOI: 10.1002/hep.25915] [Cited by in Crossref: 84] [Cited by in F6Publishing: 78] [Article Influence: 10.5] [Reference Citation Analysis]
102 Henderson PK, Herrera JL. Should We Treat Minimal/Covert Hepatic Encephalopathy, and with What? Clin Liver Dis 2015;19:487-95. [PMID: 26195203 DOI: 10.1016/j.cld.2015.04.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
103 Amodio P. Hepatic encephalopathy. In: Lee SS, Moreau R, editors. Cirrhosis: A practical guide to management. Chichester: John Wiley & Sons, Ltd; 2015. pp. 105-23. [DOI: 10.1002/9781118412640.ch11] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
104 Tabibian JH, Varghese C, LaRusso NF, O'Hara SP. The enteric microbiome in hepatobiliary health and disease. Liver Int 2016;36:480-7. [PMID: 26561779 DOI: 10.1111/liv.13009] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
105 Zakharia K, Tabibian A, Lindor KD, Tabibian JH. Complications, symptoms, quality of life and pregnancy in cholestatic liver disease. Liver Int. 2018;38:399-411. [PMID: 28921801 DOI: 10.1111/liv.13591] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
106 Gupta T, Rathi S, K Dhiman R. Managing Encephalopathy in the Outpatient Setting. Euroasian J Hepatogastroenterol 2017;7:48-54. [PMID: 29201772 DOI: 10.5005/jp-journals-10018-1211] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
107 Hirano H, Saito M, Yano Y, Momose K, Yoshida M, Tanaka A, Azuma T. Chronic liver disease questionnaire would be a primary screening tool of neuropsychiatric test detecting minimal hepatic encephalopathy of cirrhotic patients. Hepatol Res. 2015; Epub ahead of print. [PMID: 26234673 DOI: 10.1111/hepr.12442] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
108 Caraceni P, Vargas V, Solà E, Alessandria C, de Wit K, Trebicka J, Angeli P, Mookerjee RP, Durand F, Pose E, Krag A, Bajaj JS, Beuers U, Ginès P; Liverhope Consortium. The Use of Rifaximin in Patients With Cirrhosis. Hepatology 2021. [PMID: 33421158 DOI: 10.1002/hep.31708] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
109 Gluud LL, Dam G, Borre M, Les I, Cordoba J, Marchesini G, Aagaard NK, Vilstrup H. Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence? Metab Brain Dis. 2013;28:221-225. [PMID: 23275147 DOI: 10.1007/s11011-012-9372-0] [Cited by in Crossref: 61] [Cited by in F6Publishing: 45] [Article Influence: 6.8] [Reference Citation Analysis]
110 Kato A, Tanaka H, Kawaguchi T, Kanazawa H, Iwasa M, Sakaida I, Moriwaki H, Murawaki Y, Suzuki K, Okita K. Nutritional management contributes to improvement in minimal hepatic encephalopathy and quality of life in patients with liver cirrhosis: A preliminary, prospective, open-label study. Hepatol Res. 2013;43:452-458. [PMID: 22994429 DOI: 10.1111/j.1872-034x.2012.01092.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 9] [Article Influence: 3.1] [Reference Citation Analysis]
111 Ridola L, Nardelli S, Gioia S, Riggio O. How to design a multicenter clinical trial in Hepatic Encephalopathy. JCEH 2018 in press. . [PMID: 30765947 DOI: 10.1016/j.jceh.2018.02.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
112 Orr JG, Homer T, Ternent L, Newton J, McNeil CJ, Hudson M, Jones DE. Health related quality of life in people with advanced chronic liver disease. J Hepatol. 2014;61:1158-1165. [PMID: 25010259 DOI: 10.1016/j.jhep.2014.06.034] [Cited by in Crossref: 68] [Cited by in F6Publishing: 58] [Article Influence: 9.7] [Reference Citation Analysis]
113 Riedel AN, Kimer N, Jensen ASH, Dahl EK, Israelsen M, Aamann L, Gluud LL. Development and predictive validity of the cirrhosis-associated ascites symptom scale: A cohort study of 103 patients. World J Gastroenterol 2018; 24(15): 1650-1657 [PMID: 29686472 DOI: 10.3748/wjg.v24.i15.1650] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
114 Khungar V, Poordad F. Management of overt hepatic encephalopathy. Clin Liver Dis. 2012;16:73-89. [PMID: 22321466 DOI: 10.1016/j.cld.2012.03.009] [Cited by in Crossref: 44] [Cited by in F6Publishing: 31] [Article Influence: 4.9] [Reference Citation Analysis]
115 Kimer N, Pedersen JS, Busk TM, Gluud LL, Hobolth L, Krag A, Møller S, Bendtsen F; Copenhagen Rifaximin (CoRif) Study Group. Rifaximin has no effect on hemodynamics in decompensated cirrhosis: A randomized, double-blind, placebo-controlled trial. Hepatology 2017;65:592-603. [PMID: 27775818 DOI: 10.1002/hep.28898] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 7.2] [Reference Citation Analysis]
116 Umapathy S, Dhiman RK, Grover S, Duseja A, Chawla YK. Persistence of cognitive impairment after resolution of overt hepatic encephalopathy. Am J Gastroenterol. 2014;109:1011-1019. [PMID: 24777152 DOI: 10.1038/ajg.2014.107] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
117 Butterworth RF. Hepatic Encephalopathy. In: Arias IM, Alter HJ, Boyer JL, Cohen DE, Shafritz DA, Thorgeirsson SS, Wolkoff AW, editors. The Liver. Wiley; 2020. pp. 615-29. [DOI: 10.1002/9781119436812.ch48] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
118 Serper M, Kaplan DE, Lin M, Taddei TH, Parikh ND, Werner RM, Tapper EB. Inpatient Gastroenterology Consultation and Outcomes of Cirrhosis-Related Hospitalizations in Two Large National Cohorts. Dig Dis Sci 2021. [PMID: 34374917 DOI: 10.1007/s10620-021-07150-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
119 Nardone R, Taylor AC, Höller Y, Brigo F, Lochner P, Trinka E. Minimal hepatic encephalopathy: A review. Neurosci Res 2016;111:1-12. [PMID: 27153746 DOI: 10.1016/j.neures.2016.04.009] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 6.6] [Reference Citation Analysis]
120 Chaney A, Werner KT, Kipple T. Primary Care Management of Hepatic Encephalopathy: A Common Cirrhosis Complication. The Journal for Nurse Practitioners 2015;11:300-6. [DOI: 10.1016/j.nurpra.2014.11.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
121 Samanta J, Dhiman RK, Khatri A, Thumburu KK, Grover S, Duseja A, Chawla Y. Correlation between degree and quality of sleep disturbance and the level of neuropsychiatric impairment in patients with liver cirrhosis. Metab Brain Dis 2013;28:249-59. [DOI: 10.1007/s11011-013-9393-3] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 4.8] [Reference Citation Analysis]
122 Nabi E, Thacker LR, Wade JB, Sterling RK, Stravitz RT, Fuchs M, Heuman DM, Bouneva I, Sanyal AJ, Siddiqui MS. Diagnosis of covert hepatic encephalopathy without specialized tests. Clin Gastroenterol Hepatol. 2014;12:1384-1389.e2. [PMID: 24362049 DOI: 10.1016/j.cgh.2013.12.020] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 4.3] [Reference Citation Analysis]
123 Patidar KR, Thacker LR, Wade JB, Sterling RK, Sanyal AJ, Siddiqui MS, Matherly SC, Stravitz RT, Puri P, Luketic VA, Fuchs M, White MB, Noble NA, Unser AB, Gilles H, Heuman DM, Bajaj JS. Covert hepatic encephalopathy is independently associated with poor survival and increased risk of hospitalization. Am J Gastroenterol. 2014;109:1757-1763. [PMID: 25178701 DOI: 10.1038/ajg.2014.264] [Cited by in Crossref: 99] [Cited by in F6Publishing: 79] [Article Influence: 14.1] [Reference Citation Analysis]
124 Goyal O, Sidhu SS, Kishore H. Minimal hepatic encephalopathy in cirrhosis- how long to treat? Ann Hepatol. 2017;16:115-122. [PMID: 28051800 DOI: 10.5604/16652681.1226822] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
125 Piotrowski D, Boroń-Kaczmarska A. Bacterial infections and hepatic encephalopathy in liver cirrhosis-prophylaxis and treatment. Adv Med Sci 2017;62:345-56. [PMID: 28514703 DOI: 10.1016/j.advms.2016.11.009] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
126 Zullo A, Hassan C, Ridola L, Lorenzetti R, Campo SM, Riggio O. Rifaximin therapy and hepatic encephalopathy: Pros and cons. World J Gastrointest Pharmacol Ther 2012; 3(4): 62-67 [PMID: 22966484 DOI: 10.4292/wjgpt.v3.i4.62] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
127 Bloom PP, Tapper EB, Young VB, Lok AS. Microbiome therapeutics for hepatic encephalopathy. J Hepatol 2021;75:1452-64. [PMID: 34453966 DOI: 10.1016/j.jhep.2021.08.004] [Reference Citation Analysis]
128 Shen YC, Chang YH, Fang CJ, Lin YS. Zinc supplementation in patients with cirrhosis and hepatic encephalopathy: a systematic review and meta-analysis. Nutr J 2019;18:34. [PMID: 31279342 DOI: 10.1186/s12937-019-0461-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
129 Srivastava A, Chaturvedi S, Gupta RK, Malik R, Mathias A, Jagannathan NR, Jain S, Pandey CM, Yachha SK, Rathore RKS. Minimal hepatic encephalopathy in children with chronic liver disease: Prevalence, pathogenesis and magnetic resonance-based diagnosis. Journal of Hepatology 2017;66:528-36. [DOI: 10.1016/j.jhep.2016.10.026] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
130 Atluri DK, Prakash R, Mullen KD. Pathogenesis, diagnosis, and treatment of hepatic encephalopathy. J Clin Exp Hepatol. 2011;1:77-86. [PMID: 25755319 DOI: 10.1016/s0973-6883(11)60126-6] [Cited by in Crossref: 40] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
131 Bajaj JS, Heuman DM, Sanyal AJ, Hylemon PB, Sterling RK, Stravitz RT, Fuchs M, Ridlon JM, Daita K, Monteith P, Noble NA, White MB, Fisher A, Sikaroodi M, Rangwala H, Gillevet PM. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One. 2013;8:e60042. [PMID: 23565181 DOI: 10.1371/journal.pone.0060042] [Cited by in Crossref: 227] [Cited by in F6Publishing: 220] [Article Influence: 28.4] [Reference Citation Analysis]
132 徐瑞, 常江. 肝性脑病的治疗进展. 世界华人消化杂志 2015; 23(11): 1755-1762 [DOI: 10.11569/wcjd.v23.i11.1755] [Reference Citation Analysis]
133 Wang JY, Zhang NP, Chi BR, Mi YQ, Meng LN, Liu YD, Wang JB, Jiang HX, Yang JH, Xu Y, Li X, Xu JM, Zhang G, Zhou XM, Zhuge YZ, Tian DA, Ye J, Liu YL. Prevalence of minimal hepatic encephalopathy and quality of life evaluations in hospitalized cirrhotic patients in China. World J Gastroenterol 2013; 19(30): 4984-4991 [PMID: 23946605 DOI: 10.3748/wjg.v19.i30.4984] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 30] [Article Influence: 4.3] [Reference Citation Analysis]
134 Shawcross DL, Dunk AA, Jalan R, Kircheis G, de Knegt RJ, Laleman W, Ramage JK, Wedemeyer H, Morgan IE; New Insights Steering Committee. How to diagnose and manage hepatic encephalopathy: a consensus statement on roles and responsibilities beyond the liver specialist. Eur J Gastroenterol Hepatol. 2016;28:146-152. [PMID: 26600154 DOI: 10.1097/meg.0000000000000529] [Cited by in Crossref: 22] [Cited by in F6Publishing: 9] [Article Influence: 4.4] [Reference Citation Analysis]
135 Zhan T, Stremmel W. The diagnosis and treatment of minimal hepatic encephalopathy. Dtsch Arztebl Int. 2012;109:180-187. [PMID: 22470407 DOI: 10.3238/arztebl.2012.0180] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
136 Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, Weissenborn K, Wong P. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60:715-735. [PMID: 25042402 DOI: 10.1002/hep.27210] [Cited by in Crossref: 879] [Cited by in F6Publishing: 681] [Article Influence: 125.6] [Reference Citation Analysis]
137 Waghray N, Waghray A, Mullen K. Treatment options for covert hepatic encephalopathy. Curr Treat Options Gastroenterol. 2014;12:229-241. [PMID: 24623592 DOI: 10.1007/s11938-014-0014-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
138 Lauridsen MM, Schaffalitzky de Muckadell OB, Vilstrup H. Minimal hepatic encephalopathy characterized by parallel use of the continuous reaction time and portosystemic encephalopathy tests. Metab Brain Dis. 2015;30:1187-1192. [PMID: 26016624 DOI: 10.1007/s11011-015-9688-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]